NasdaqGS - Nasdaq Real Time Price USD

argenx SE (ARGX)

Compare

656.26

+7.00

+(1.08%)

At close: January 10 at 4:00:01 PM EST

656.26

0.00

(0.00%)

After hours: January 10 at 5:03:40 PM EST

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A repl

GlobeNewswire 5 days ago

ARGNF

ARGX
+1.08%
Exploring High Growth Tech Stocks for January 2025

As we enter January 2025, global markets are navigating a landscape marked by fluctuating consumer confidence and mixed economic indicators, with major U.S. stock indexes experiencing moderate gains amidst a holiday-shortened trading week. In this environment, identifying high-growth tech stocks requires careful consideration of factors such as innovation potential and market adaptability, particularly as the technology-heavy Nasdaq Composite continues to show resilience despite recent...

Simply Wall St. 10 days ago

ARGNF

ARGX
+1.08%
Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment

Argenx Se ( (ARGX) ) has provided an update. Argenx SE announced that Japan’s Ministry of Health, Labour and Welfare has approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval marks the first time the neonatal Fc receptor blocker has been authorized for CIDP treatment, providing patients with a convenient at-home self-injection option. The approval is based on the results of the ADHERE trial, which demonstrated significant clinical improvements i

TipRanks 14 days ago

ARGNF

ARGX
+1.08%
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio approved in Japan for three indications – first country globally with access across three indications December 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Japan’s Ministry of

GlobeNewswire 15 days ago

ARGNF

ARGX
+1.08%
Is Argenx SE (ARGX) the Best Performing Biotech Stock in 2024?

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Argenx SE (NASDAQ:ARGX) stands against the other biotech stocks. The Booming Biotechnology Sector The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and […]

Insider Monkey 19 days ago

ARGX
+1.08%
Here’s Why argenx SE (ARGX) Surged in Q3

PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S. employment and the associated concerns that U.S. interest rates may have been maintained at levels higher than necessary to moderate the pace of inflation, U.S. […]

Insider Monkey 30 days ago

ARGX
+1.08%
Should You Increase Your Holdings in argenx SE (ARGX)?

TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. Within equities, smaller or value-oriented stocks in developed economies yielded higher, whereas emerging markets saw the opposite trend. In the third quarter, the strategy returned 4.96% (gross) and […]

Insider Monkey last month

ARGX
+1.08%
Three Stocks Estimated To Be Undervalued In December 2024

As global markets continue to reach record highs, driven by strong gains in major indices like the Dow Jones Industrial Average and S&P 500, investors are navigating a landscape influenced by geopolitical developments and domestic policy shifts. Amidst this environment, identifying undervalued stocks can offer potential opportunities for those looking to capitalize on discrepancies between market price and intrinsic value.

Simply Wall St. last month

SWEC-A.ST

SWEC-B.ST

ESRCF
Spotlight On High Growth Tech Stocks This December 2024

As global markets continue to experience robust growth, with U.S. small-cap indices like the Russell 2000 reaching record highs, investor sentiment remains buoyed by domestic policy decisions and geopolitical developments. In this environment of heightened market activity and economic indicators showing mixed signals, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation capabilities and adaptability to shifting economic landscapes.

Simply Wall St. last month

ARGNF

ARGX
+1.08%
GTK.NZ
Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now?

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a look at where Argenx SE (NASDAQ:ARGX) stands against the other high growth healthcare stocks. Global Healthcare Spending Trends and Investment Opportunities During lean economic times, investing in healthcare stocks is […]

Insider Monkey last month

ARGX
+1.08%
argenx to Present at Upcoming Investor Conferences

November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December. Citi’s 2024 Global Healthcare Conference. Fireside chat on Tuesday, December 3 at 1:45 p.m. ET in Miami, FL. 7th Annual Evercore I&I HealthCONx Conference. Fireside chat on Wedn

GlobeNewswire last month

ARGNF

ARGX
+1.08%
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial

Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement.

BioPharma Dive last month

HALO

EVT.DE

ARGX
+1.08%
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disease

GlobeNewswire last month

ARGNF

ARGX
+1.08%
Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by […]

Insider Monkey last month

ARGX
+1.08%
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)]

GlobeNewswire last month

ARGNF

ARGX
+1.08%
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

SHANGHAI & CAMBRIDGE, Mass., November 11, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved for CIDP

Business Wire last month

ZLAB
+4.12%
ARGNF

ARGX
+1.08%
Why Argenx (ARGX) Might be Well Poised for a Surge

Argenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks 2 months ago

ARGX
+1.08%
argenx to Participate at Upcoming Investor Conferences

November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in November: Guggenheim Inaugural Healthcare Innovation Conference. Fireside chat on Tuesday, November 12, 2024 at 2:30 p.m. ET in Boston, MA. Jefferies London Healthcare Conference. Manageme

GlobeNewswire 2 months ago

ARGNF

ARGX
+1.08%
Three Value Stocks Priced Below Estimated Worth In November 2024

As global markets navigate a period of heightened economic activity and mixed signals from earnings reports, investors are keenly observing the performance of major indices, which have seen fluctuations amid busy data weeks. With value stocks showing resilience compared to their growth counterparts, this environment presents an opportunity to identify stocks that may be trading below their intrinsic worth. In such a climate, finding undervalued stocks requires a focus on strong fundamentals...

Simply Wall St. 2 months ago

ARGNF

ARGX
+1.08%
GFL
High Growth Tech Stocks To Watch In November 2024

In a week marked by busy earnings reports and economic data releases, global markets saw major indices like the Nasdaq Composite and S&P MidCap 400 hit record highs before retreating, while small-cap stocks showed resilience compared to their larger counterparts. Amidst this backdrop of cautious optimism and mixed signals from the labor market, investors are keenly watching high-growth tech stocks that demonstrate strong fundamentals and potential for innovation-driven expansion.

Simply Wall St. 2 months ago

TIPSMUSIC.BO

TIPSMUSIC.NS

ARGNF

Performance Overview

Return	ARGX	BEL 20
YTD	+5.86%	+0.19%
1-Year	+64.11%	+13.76%
3-Year	+109.95%	-1.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

argenx SE (ARGX)

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

Exploring High Growth Tech Stocks for January 2025

Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Is Argenx SE (ARGX) the Best Performing Biotech Stock in 2024?

Here’s Why argenx SE (ARGX) Surged in Q3

Should You Increase Your Holdings in argenx SE (ARGX)?

Three Stocks Estimated To Be Undervalued In December 2024

Spotlight On High Growth Tech Stocks This December 2024

Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now?

argenx to Present at Upcoming Investor Conferences

Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Why Argenx (ARGX) Might be Well Poised for a Surge

argenx to Participate at Upcoming Investor Conferences

Three Value Stocks Priced Below Estimated Worth In November 2024

High Growth Tech Stocks To Watch In November 2024

Performance Overview